메뉴 건너뛰기




Volumn 8, Issue 1, 2018, Pages

Canagliflozin inhibits interleukin-1β-stimulated cytokine and chemokine secretion in vascular endothelial cells by AMP-activated protein kinase-dependent and -independent mechanisms

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFLAMMATORY AGENT; CANAGLIFLOZIN; CHEMOKINE; CYTOKINE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; INTERLEUKIN 1BETA;

EID: 85044585390     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/s41598-018-23420-4     Document Type: Article
Times cited : (195)

References (50)
  • 1
    • 84904543855 scopus 로고    scopus 로고
    • Anti-inflammatory therapies for cardiovascular disease
    • Ridker, P. M. & Luscher, T. F. Anti-inflammatory therapies for cardiovascular disease. Eur. Heart J. 35, 1782-1791 (2014).
    • (2014) Eur. Heart J. , vol.35 , pp. 1782-1791
    • Ridker, P.M.1    Luscher, T.F.2
  • 2
    • 85027200588 scopus 로고    scopus 로고
    • Mirroring the CANTOS revolution: Is anti-inflammatory therapy for diabetes just around the corner?
    • Tenenbaum, A. & Fisman, E. Z. Mirroring the CANTOS revolution: is anti-inflammatory therapy for diabetes just around the corner? Cardiovasc. Diabetol. 16, 91 (2017).
    • (2017) Cardiovasc. Diabetol. , vol.16 , pp. 91
    • Tenenbaum, A.1    Fisman, E.Z.2
  • 3
    • 77957280402 scopus 로고    scopus 로고
    • Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS
    • Makó, V. et al. Proinflammatory activation pattern of human umbilical vein endothelial cells induced by IL-1β, TNF-α, and LPS. Cytometry A. 77, 962-970 (2010).
    • (2010) Cytometry A. , vol.77 , pp. 962-970
    • Makó, V.1
  • 4
    • 84863700565 scopus 로고    scopus 로고
    • Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation
    • Salt, I. P. & Palmer, T. M. Exploiting the anti-inflammatory effects of AMP-activated protein kinase activation. Expert Opin. Investig. Drugs. 21, 1155-1167 (2012).
    • (2012) Expert Opin. Investig. Drugs. , vol.21 , pp. 1155-1167
    • Salt, I.P.1    Palmer, T.M.2
  • 5
    • 84901807090 scopus 로고    scopus 로고
    • The TLR and IL-1 signalling network at a glance
    • Cohen, P. The TLR and IL-1 signalling network at a glance. J. Cell. Sci. 127, 2383-2390 (2014).
    • (2014) J. Cell. Sci. , vol.127 , pp. 2383-2390
    • Cohen, P.1
  • 6
    • 84856297871 scopus 로고    scopus 로고
    • Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies
    • Davies, C. & Tournier, C. Exploring the function of the JNK (c-Jun N-terminal kinase) signalling pathway in physiological and pathological processes to design novel therapeutic strategies. Biochem. Soc. Trans. 40, 85-89 (2012).
    • (2012) Biochem. Soc. Trans. , vol.40 , pp. 85-89
    • Davies, C.1    Tournier, C.2
  • 7
    • 85019072998 scopus 로고    scopus 로고
    • Sodium glucose co-transporters and their inhibition: Clinical physiology
    • Ferrannini, E. Sodium glucose co-transporters and their inhibition: clinical physiology. Cell Metab. 26, 27-38 (2017).
    • (2017) Cell Metab. , vol.26 , pp. 27-38
    • Ferrannini, E.1
  • 8
    • 84944800184 scopus 로고    scopus 로고
    • Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes
    • Zinman, B. et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N. Engl. J. Med. 373, 2117-2128 (2015).
    • (2015) N. Engl. J. Med. , vol.373 , pp. 2117-2128
    • Zinman, B.1
  • 9
    • 85023777061 scopus 로고    scopus 로고
    • CANVAS program collaborative group. Canagliflozin and cardiovascular and renal events in type 2 diabetes
    • Neal, B. et al. CANVAS Program Collaborative Group. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N. Engl. J. Med. 377, 644-657 (2017).
    • (2017) N. Engl. J. Med. , vol.377 , pp. 644-657
    • Neal, B.1
  • 10
    • 84964773926 scopus 로고    scopus 로고
    • SGLT2 inhibitors and cardiovascular risk: Lessons learned from the EMPA-REG OUTCOME study
    • Abdul-Ghani, M., Del Prato, S., Chilton, R. & DeFronzo, R. A. SGLT2 inhibitors and cardiovascular risk: lessons learned from the EMPA-REG OUTCOME study. Diabetes Care. 39, 717-725 (2016).
    • (2016) Diabetes Care. , vol.39 , pp. 717-725
    • Abdul-Ghani, M.1    Del Prato, S.2    Chilton, R.3    DeFronzo, R.A.4
  • 11
    • 84964507777 scopus 로고    scopus 로고
    • SGLT2 inhibition and cardiovascular events: Why did EMPAREG outcomes surprise and what were the likely mechanisms?
    • Sattar, N., McLaren, J., Kristensen, S. L., Preiss, D. & McMurray, J. J. SGLT2 inhibition and cardiovascular events: why did EMPAREG outcomes surprise and what were the likely mechanisms? Diabetologia 59, 1333-1339 (2016).
    • (2016) Diabetologia , vol.59 , pp. 1333-1339
    • Sattar, N.1    McLaren, J.2    Kristensen, S.L.3    Preiss, D.4    McMurray, J.J.5
  • 12
    • 84975853831 scopus 로고    scopus 로고
    • CV protection in the EMPA-REG OUTCOME trial: A "thrifty substrate" hypothesis
    • Ferrannini, E., Mark, M. & Mayoux, E. CV protection in the EMPA-REG OUTCOME trial: a "thrifty substrate" hypothesis. Diabetes Care. 39, 1108-1114 (2016).
    • (2016) Diabetes Care. , vol.39 , pp. 1108-1114
    • Ferrannini, E.1    Mark, M.2    Mayoux, E.3
  • 13
    • 85026920030 scopus 로고    scopus 로고
    • The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipidmetabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice
    • Nakatsu, Y. et al. The SGLT2 inhibitor luseogliflozin rapidly normalizes aortic mRNA levels of inflammation-related but not lipidmetabolism-related genes and suppresses atherosclerosis in diabetic ApoE KO mice. Int. J. Mol. Sci. 18, 1704 (2017).
    • (2017) Int. J. Mol. Sci. , vol.18 , pp. 1704
    • Nakatsu, Y.1
  • 14
    • 84995768100 scopus 로고    scopus 로고
    • The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet
    • Han, J. H. et al. The beneficial effects of empagliflozin, an SGLT2 inhibitor, on atherosclerosis in ApoE -/- mice fed a western diet. Diabetologia 60, 364-376 (2017).
    • (2017) Diabetologia , vol.60 , pp. 364-376
    • Han, J.H.1
  • 15
    • 84911942671 scopus 로고    scopus 로고
    • The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity
    • Oelze, M. et al. The sodium-glucose co-transporter 2 inhibitor empagliflozin improves diabetes-induced vascular dysfunction in the streptozotocin diabetes rat model by interfering with oxidative stress and glucotoxicity. PLoS One. 9, e112394 (2014).
    • (2014) PLoS One. , vol.9 , pp. e112394
    • Oelze, M.1
  • 16
    • 85017220425 scopus 로고    scopus 로고
    • Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse
    • Salim, H. M. et al. Glycemic control with ipragliflozin, a novel selective SGLT2 inhibitor, ameliorated endothelial dysfunction in streptozotocin-induced diabetic mouse. Front. Cardiovasc. Med. 3, 43 (2016).
    • (2016) Front. Cardiovasc. Med. , vol.3 , pp. 43
    • Salim, H.M.1
  • 17
    • 85021409196 scopus 로고    scopus 로고
    • The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats
    • Steven, S. et al. The SGLT2 inhibitor empagliflozin improves the primary diabetic complications in ZDF rats. Redox Biol. 13, 370-385 (2017).
    • (2017) Redox Biol. , vol.13 , pp. 370-385
    • Steven, S.1
  • 18
    • 84946434020 scopus 로고    scopus 로고
    • SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery
    • Han, Y. et al. SGLT inhibitors attenuate NO-dependent vascular relaxation in the pulmonary artery but not in the coronary artery. Am. J. Physiol. Lung Cell. Mol. Physiol. 309, L1027-1036 (2015).
    • (2015) Am. J. Physiol. Lung Cell. Mol. Physiol. , vol.309 , pp. L1027-L1036
    • Han, Y.1
  • 19
    • 84987624200 scopus 로고    scopus 로고
    • The Na +/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels
    • Hawley, S. A. et al. The Na +/glucose cotransporter inhibitor canagliflozin activates AMPK by inhibiting mitochondrial function and increasing cellular AMP levels. Diabetes 65, 2784-2794 (2016).
    • (2016) Diabetes , vol.65 , pp. 2784-2794
    • Hawley, S.A.1
  • 20
    • 84992195114 scopus 로고    scopus 로고
    • The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration
    • Villani, L. A. et al. The diabetes medication Canagliflozin reduces cancer cell proliferation by inhibiting mitochondrial complex-I supported respiration. Mol. Metab. 5, 1048-1056 (2016).
    • (2016) Mol. Metab. , vol.5 , pp. 1048-1056
    • Villani, L.A.1
  • 21
    • 85020822242 scopus 로고    scopus 로고
    • AMPK: Mechanisms of cellular energy sensing and restoration of metabolic balance
    • Garcia, D. & Shaw, R. J. AMPK: mechanisms of cellular energy sensing and restoration of metabolic balance. Mol. Cell. 66, 789-800 (2017).
    • (2017) Mol. Cell. , vol.66 , pp. 789-800
    • Garcia, D.1    Shaw, R.J.2
  • 22
    • 85019662904 scopus 로고    scopus 로고
    • AMP-activated protein kinase: An ubiquitous signaling pathway with key roles in the cardiovascular system
    • Salt, I. P. & Hardie, D. G. AMP-activated protein kinase: an ubiquitous signaling pathway with key roles in the cardiovascular system. Circ. Res. 120, 1825-1841 (2017).
    • (2017) Circ. Res. , vol.120 , pp. 1825-1841
    • Salt, I.P.1    Hardie, D.G.2
  • 23
    • 85018253813 scopus 로고    scopus 로고
    • SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor
    • Ye, Y., Bajaj, M., Yang, H. C., Perez-Polo, J. R. & Birnbaum, Y. SGLT-2 inhibition with dapagliflozin reduces the activation of the Nlrp3/ASC inflammasome and attenuates the development of diabetic cardiomyopathy in mice with type 2 diabetes. Further augmentation of the effects with saxagliptin, a DPP4 inhibitor. Cardiovasc. Drugs Ther. 31, 119-132 (2017).
    • (2017) Cardiovasc. Drugs Ther. , vol.31 , pp. 119-132
    • Ye, Y.1    Bajaj, M.2    Yang, H.C.3    Perez-Polo, J.R.4    Birnbaum, Y.5
  • 24
    • 14344257169 scopus 로고    scopus 로고
    • AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells
    • Cacicedo, J. M. et al. AMPK inhibits fatty acid-induced increases in NF-kappaB transactivation in cultured human umbilical vein endothelial cells. Biochem. Biophys. Res. Commun. 324, 1204-1209 (2004).
    • (2004) Biochem. Biophys. Res. Commun. , vol.324 , pp. 1204-1209
    • Cacicedo, J.M.1
  • 25
    • 79958078455 scopus 로고    scopus 로고
    • Nitric oxide-induced activation of the AMP-activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in endothelial cells
    • Bess, E., Fisslthaler, B., Frömel, T. & Fleming, I. Nitric oxide-induced activation of the AMP-activated protein kinase α2 subunit attenuates IκB kinase activity and inflammatory responses in endothelial cells. PLoS One. 6, e20848 (2011).
    • (2011) PLoS One. , vol.6 , pp. e20848
    • Bess, E.1    Fisslthaler, B.2    Frömel, T.3    Fleming, I.4
  • 26
    • 57549088860 scopus 로고    scopus 로고
    • Inhibition of tumour necrosis factor-alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase
    • Ewart, M. A., Kohlhaas, C. F. & Salt, I. P. Inhibition of tumour necrosis factor-alpha-stimulated monocyte adhesion to human aortic endothelial cells by AMP-activated protein kinase. Arterioscler. Thromb. Vasc. Biol. 28, 2255-2257 (2008).
    • (2008) Arterioscler. Thromb. Vasc. Biol. , vol.28 , pp. 2255-2257
    • Ewart, M.A.1    Kohlhaas, C.F.2    Salt, I.P.3
  • 27
    • 84996807783 scopus 로고    scopus 로고
    • Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation
    • Mancini, S. J. et al. Activation of AMP-activated protein kinase rapidly suppresses multiple pro-inflammatory pathways in adipocytes including IL-1 receptor-associated kinase-4 phosphorylation. Mol. Cell. Endocrinol. 440, 44-56 (2017).
    • (2017) Mol. Cell. Endocrinol. , vol.440 , pp. 44-56
    • Mancini, S.J.1
  • 28
    • 84942506312 scopus 로고    scopus 로고
    • Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor
    • Devineni, D. & Polidori, D. Clinical pharmacokinetic, pharmacodynamic, and drug-drug interaction profile of canagliflozin, a sodium-glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 54, 1027-1041 (2015).
    • (2015) Clin. Pharmacokinet. , vol.54 , pp. 1027-1041
    • Devineni, D.1    Polidori, D.2
  • 29
    • 79951897566 scopus 로고    scopus 로고
    • Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus
    • Kasichayanula, S. et al. Pharmacokinetics and pharmacodynamics of dapagliflozin, a novel selective inhibitor of sodium-glucose co-transporter type 2, in Japanese subjects without and with type 2 diabetes mellitus. Diabetes Obes. Metab. 13, 357-365 (2011).
    • (2011) Diabetes Obes. Metab. , vol.13 , pp. 357-365
    • Kasichayanula, S.1
  • 30
    • 84872111344 scopus 로고    scopus 로고
    • Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers
    • Brand, T., Macha, S., Mattheus, M., Pinnetti, S. & Woerle, H. J. Pharmacokinetics of empagliflozin, a sodium glucose cotransporter-2 (SGLT-2) inhibitor, coadministered with sitagliptin in healthy volunteers. Adv. Ther. 29, 889-899 (2012).
    • (2012) Adv. Ther. , vol.29 , pp. 889-899
    • Brand, T.1    Macha, S.2    Mattheus, M.3    Pinnetti, S.4    Woerle, H.J.5
  • 31
    • 84896826460 scopus 로고    scopus 로고
    • Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor
    • Scheen, A. J. Pharmacokinetic and pharmacodynamic profile of empagliflozin, a sodium glucose co-transporter 2 inhibitor. Clin. Pharmacokinet. 53, 213-225 (2014).
    • (2014) Clin. Pharmacokinet. , vol.53 , pp. 213-225
    • Scheen, A.J.1
  • 32
    • 0033815967 scopus 로고    scopus 로고
    • Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase
    • Woods, A. et al. Characterization of the role of AMP-activated protein kinase in the regulation of glucose-activated gene expression using constitutively active and dominant negative forms of the kinase. Mol. Cell. Biol. 20, 6704-6711 (2000).
    • (2000) Mol. Cell. Biol. , vol.20 , pp. 6704-6711
    • Woods, A.1
  • 33
    • 45549088112 scopus 로고    scopus 로고
    • Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase
    • Boyle, J. G. et al. Rosiglitazone stimulates nitric oxide synthesis in human aortic endothelial cells via AMP-activated protein kinase. J. Biol. Chem. 283, 11210-11217 (2008).
    • (2008) J. Biol. Chem. , vol.283 , pp. 11210-11217
    • Boyle, J.G.1
  • 34
    • 84890963021 scopus 로고    scopus 로고
    • Structural basis of AMPK regulation by small molecule activators
    • Xiao, B. et al. Structural basis of AMPK regulation by small molecule activators. Nat. Commun. 4, 3017 (2013).
    • (2013) Nat. Commun. , vol.4 , pp. 3017
    • Xiao, B.1
  • 35
    • 0030071339 scopus 로고    scopus 로고
    • MTS interferon assay: A simplified cellular dehydrogenase assay for interferon activity using a water-soluble tetrazolium salt
    • Khabar, K. S. et al. MTS interferon assay: a simplified cellular dehydrogenase assay for interferon activity using a water-soluble tetrazolium salt. J. Interferon Cytokine Res. 16, 31-33 (1996).
    • (1996) J. Interferon Cytokine Res. , vol.16 , pp. 31-33
    • Khabar, K.S.1
  • 36
    • 85006515958 scopus 로고    scopus 로고
    • Transendothelial glucose transport is not restricted by extracellular hyperglycaemia
    • Tumova, S., Kerimi, A., Porter, K. E. & Williamson, G. Transendothelial glucose transport is not restricted by extracellular hyperglycaemia. Vascul. Pharmacol. 87, 219-229 (2016).
    • (2016) Vascul. Pharmacol. , vol.87 , pp. 219-229
    • Tumova, S.1    Kerimi, A.2    Porter, K.E.3    Williamson, G.4
  • 37
    • 84885852033 scopus 로고    scopus 로고
    • Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway
    • Chen, M. L. et al. Absorption of resveratrol by vascular endothelial cells through passive diffusion and an SGLT1-mediated pathway. J. Nutr. Biochem. 24, 1823-1829 (2013).
    • (2013) J. Nutr. Biochem. , vol.24 , pp. 1823-1829
    • Chen, M.L.1
  • 38
    • 84857099986 scopus 로고    scopus 로고
    • Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models
    • Liang, Y. et al. Effect of canagliflozin on renal threshold for glucose, glycemia, and body weight in normal and diabetic animal models. PLoS One 7, e30555 (2012).
    • (2012) PLoS One , vol.7 , pp. e30555
    • Liang, Y.1
  • 39
    • 85019618220 scopus 로고    scopus 로고
    • The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model
    • Joubert, M. et al. The sodium-glucose cotransporter 2 inhibitor dapagliflozin prevents cardiomyopathy in a diabetic lipodystrophic mouse model. Diabetes 66, 1030-1040 (2017).
    • (2017) Diabetes , vol.66 , pp. 1030-1040
    • Joubert, M.1
  • 40
    • 36549040859 scopus 로고    scopus 로고
    • The selectivity of protein kinase inhibitors: A further update
    • Bain, J. et al. The selectivity of protein kinase inhibitors: a further update. Biochem. J. 408, 297-315 (2007).
    • (2007) Biochem. J. , vol.408 , pp. 297-315
    • Bain, J.1
  • 41
    • 85047689953 scopus 로고
    • 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells?
    • Corton, J. M., Gillespie, J. G., Hawley, S. A. & Hardie, D. G. 5-aminoimidazole-4-carboxamide ribonucleoside. A specific method for activating AMP-activated protein kinase in intact cells? Eur. J. Biochem. 229, 558-565 (1995).
    • (1995) Eur. J. Biochem. , vol.229 , pp. 558-565
    • Corton, J.M.1    Gillespie, J.G.2    Hawley, S.A.3    Hardie, D.G.4
  • 42
    • 84857926956 scopus 로고    scopus 로고
    • Subunit composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug target identification
    • Pinter, K., Jefferson, A., Czibik, G., Watkins, H. & Redwood, C. Subunit composition of AMPK trimers present in the cytokinetic apparatus: Implications for drug target identification. Cell Cycle 11, 917-921 (2012).
    • (2012) Cell Cycle , vol.11 , pp. 917-921
    • Pinter, K.1    Jefferson, A.2    Czibik, G.3    Watkins, H.4    Redwood, C.5
  • 43
    • 81755174323 scopus 로고    scopus 로고
    • AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300
    • Zhang, Y., Qiu, J., Wang, X. & Xia, M. AMP-activated protein kinase suppresses endothelial cell inflammation through phosphorylation of transcriptional coactivator p300. Arterioscler. Thromb. Vasc. Biol. 31, 2897-2908 (2011).
    • (2011) Arterioscler. Thromb. Vasc. Biol. , vol.31 , pp. 2897-2908
    • Zhang, Y.1    Qiu, J.2    Wang, X.3    Xia, M.4
  • 44
    • 34247340098 scopus 로고    scopus 로고
    • MTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells
    • Schreml, S., Lehle, K., Birnbaum, D. E. & Preuner, J. G. mTOR-inhibitors simultaneously inhibit proliferation and basal IL-6 synthesis of human coronary artery endothelial cells. Int. Immunopharmacol. 7, 781-790 (2007).
    • (2007) Int. Immunopharmacol. , vol.7 , pp. 781-790
    • Schreml, S.1    Lehle, K.2    Birnbaum, D.E.3    Preuner, J.G.4
  • 45
    • 84875873193 scopus 로고    scopus 로고
    • Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells
    • Wang, C. et al. Rapamycin-treated human endothelial cells preferentially activate allogeneic regulatory T cells. J. Clin. Invest. 123, 1677-1693 (2013).
    • (2013) J. Clin. Invest. , vol.123 , pp. 1677-1693
    • Wang, C.1
  • 46
    • 84880057785 scopus 로고    scopus 로고
    • AMP-dependent kinase inhibits oxidative stress-induced caveolin-1 phosphorylation and endocytosis by suppressing the dissociation between c-Abl and Prdx1 proteins in endothelial cells
    • Takeuchi, K. et al. AMP-dependent kinase inhibits oxidative stress-induced caveolin-1 phosphorylation and endocytosis by suppressing the dissociation between c-Abl and Prdx1 proteins in endothelial cells. J. Biol. Chem. 288, 20581-20591 (2013).
    • (2013) J. Biol. Chem. , vol.288 , pp. 20581-20591
    • Takeuchi, K.1
  • 47
    • 84994908860 scopus 로고    scopus 로고
    • Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling
    • Rutherford, C. et al. Phosphorylation of Janus kinase 1 (JAK1) by AMP-activated protein kinase (AMPK) links energy sensing to anti-inflammatory signaling. Sci. Signal. 9, ra109 (2016).
    • (2016) Sci. Signal. , vol.9 , pp. ra109
    • Rutherford, C.1
  • 48
    • 84997354438 scopus 로고    scopus 로고
    • Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice
    • Naznin, F. et al. Canagliflozin, a sodium glucose cotransporter 2 inhibitor, attenuates obesity-induced inflammation in the nodose ganglion, hypothalamus, and skeletal muscle of mice. Eur. J. Pharmacol. 794, 37-44 (2017).
    • (2017) Eur. J. Pharmacol. , vol.794 , pp. 37-44
    • Naznin, F.1
  • 49
    • 0030592623 scopus 로고    scopus 로고
    • The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro
    • Woods, A., Salt, I., Scott, J., Hardie, D. G. & Carling, D. The alpha1 and alpha2 isoforms of the AMP-activated protein kinase have similar activities in rat liver but exhibit differences in substrate specificity in vitro. FEBS Lett. 397, 347-351 (1996).
    • (1996) FEBS Lett. , vol.397 , pp. 347-351
    • Woods, A.1    Salt, I.2    Scott, J.3    Hardie, D.G.4    Carling, D.5
  • 50
    • 85009460365 scopus 로고    scopus 로고
    • Protein kinase C phosphorylates AMP-activated protein kinase α1 Ser487
    • Heathcote, H. R. et al. Protein kinase C phosphorylates AMP-activated protein kinase α1 Ser487. Biochem. J. 473, 4681-4697 (2016).
    • (2016) Biochem. J. , vol.473 , pp. 4681-4697
    • Heathcote, H.R.1


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.